1. |
EU legislation needed for public access to drug information? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 2-2
&NA;,
Preview
|
PDF (856KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
Hepatitis Ca virus to be reckoned with |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 3-4
Karen Birmingham,
Preview
|
PDF (1528KB)
|
|
摘要:
While HIV has undoubtedly been the viral focus of attention in recent years, hepatitis C virus (HCV) is now forcing its way onto the world's healthcare stage. The new attention that HCV has received since the beginning of the year is well deserved - this virus infects 5 times as many people as HIV worldwide. One reason for this is that no effective screening test existed for HCV, which is transmitted via the blood, prior to 1986 and it took an additional 6 years to develop a reliable blood test. Thus, vast numbers of individuals joined the ranks of infected patients via transmission of tainted blood products. Consequently, millions of people are now moving through the natural course of the disease at varying speeds, and in an effort to divert catastrophe, researchers and clinicians are hurriedly trying to apply the therapeutic lessons learned from HIV to HCV. The potential market size for therapeutic intervention is huge and it is no surprise that several major pharmaceutical and biotechnology companies are involved in what has become an extremely competitive field.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 5-5
&NA;,
Preview
|
PDF (740KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
Mitoxantrone plus prednisone justified in prostate cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 6-6
&NA;,
Preview
|
PDF (759KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
Oprelvekin protects against GVHD in murine BMT model |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 7-7
&NA;,
Preview
|
PDF (692KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 8-8
&NA;,
Preview
|
PDF (771KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
Abacavira new NRTI on the horizon |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 9-10
Wayne Elwood,
Preview
|
PDF (1568KB)
|
|
摘要:
Although many patients achieve viral suppression to levels below detection after initiating highly active anti-retroviral therapy (HAART) in clinical trials, about 50% of infected patients fail to respond to treatment in the ‘real world’. One of the main reasons for treatment failure is lack of compliance with HAART regimens as a result of failure to adhere to complex drug administration schedules, large pill burdens, and the incidence of adverse effects. One way to address these limitations is to develop new and more potent drugs that can be administered more conveniently, delegates were told at the 12th World AIDS Conference [Geneva, Switzerland; June 1998]. Abacavir [‘Ziagen’; Glaxo Wellcome] is a potent second-generation nucleoside reverse transcriptase inhibitor (NRTI) that is in late phase III clinical development. Abacavir may help simplify HAART regimens since it can be administered as 1 tablet twice daily, has no food or fluid restrictions, and preliminary data suggest no drug interactions. Results from several studies of abacavir were presented at the meeting.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 10-10
&NA;,
Preview
|
PDF (757KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 11-11
&NA;,
Preview
|
PDF (769KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
Budesonide superior to mesalazine in active Crohn's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1150,
1998,
Page 12-12
&NA;,
Preview
|
PDF (775KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|